Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
A Randomized, Open-label, Positive-controlled, Multicenter Phase Ш Study Comparing Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Therapy
Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
A PHASE3 clinical study on Recurrent Metastatic Nasopharyngeal Carcinoma, this trial is actively recruiting participants. The trial is conducted by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and has accumulated 3 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.